Biomarkers of bone health and osteoporosis riskEASTELLT, Richard; HANNON, Rosemary A.Proceedings of the Nutrition Society. 2008, Vol 67, Num 2, pp 157-162, issn 0029-6651, 6 p.Conference Paper

Effect of Stopping Risedronate after Long-Term Treatment on Bone TurnoverEASTELL, Richard; HANNON, Rosemary A; WENDEROTH, Dietrich et al.The Journal of clinical endocrinology and metabolism. 2011, Vol 96, Num 11, pp 3367-3373, issn 0021-972X, 7 p.Article

Risk Factors for Vertebral and Nonvertebral Fracture Over 10 Years : A Population-Based Study in WomenFINIGAN, Judith; GREENFIELD, Diana M; BLUMSOHN, Aubrey et al.Journal of bone and mineral research (Print). 2008, Vol 23, Num 1, pp 75-85, issn 0884-0431, 11 p.Article

The use of a point of care device for monitoring the bone resorption biomarker urinary N-telopeptide in cancer patients with bone metastasesLESTER, Jim E; BROWN, Janet E; HANNON, Rosemary A et al.Bone (New York, NY). 2010, Vol 46, Num 3, pp 801-805, issn 8756-3282, 5 p.Article

Effect of Anastrozole on Bone Mineral Density : 5-Year Results From the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230EASTELL, Richard; ADAMS, Judith E; COLEMAN, Robert E et al.Journal of clinical oncology. 2008, Vol 26, Num 7, pp 1051-1058, issn 0732-183X, 8 p.Article

Absence of marked seasonal change in bone turnover: A longitudinal and multicenter cross-sectional studyBLUMSOHN, Aubrey; NAYLOR, Kim E; TIMM, Wolfram et al.Journal of bone and mineral research (Print). 2003, Vol 18, Num 7, pp 1274-1281, issn 0884-0431, 8 p.Article

Effects of third generation aromatase inhibitors on bone health and other safety parameters : Results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal womenMCCLOSKEY, Eugene V; HANNON, Rosemary A; LAKNER, Geza et al.European journal of cancer (1990). 2007, Vol 43, Num 17, pp 2523-2531, issn 0959-8049, 9 p.Article

Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorptionHANNON, Rosemary A; CLOWES, Jackie A; EAGLETON, Alison C et al.Bone (New York, NY). 2004, Vol 34, Num 1, pp 187-194, issn 8756-3282, 8 p.Article

Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a Phase I studyHANNON, Rosemary A; FINKELMAN, Richard D; CLACK, Glen et al.Bone (New York, NY). 2012, Vol 50, Num 4, pp 885-892, issn 8756-3282, 8 p.Article

Prevention of Aromatase Inhibitor-Induced Bone Loss Using Risedronate: The SABRE TrialVAN POZNAK, Catherine; HANNON, Rosemary A; MACKEY, John R et al.Journal of clinical oncology. 2010, Vol 28, Num 6, pp 967-975, issn 0732-183X, 9 p.Article

Prevention of Anastrozole-Induced Bone Loss with Monthly Oral Ibandronate during Adjuvant Aromatase Inhibitor Therapy for Breast CancerLESTER, James E; DODWELL, David; PUROHIT, Omprakash P et al.Clinical cancer research (Print). 2008, Vol 14, Num 19, pp 6336-6342, issn 1078-0432, 7 p.Article

Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumoursSANTINI, Daniele; VINCENZI, Bruno; CARAGLIA, Michele et al.Oncology reports. 2006, Vol 15, Num 5, pp 1351-1357, issn 1021-335X, 7 p.Article

Effect of an aromatase inhibitor on BMD and bone turnover markers : 2-year results of the anastrozole, tamoxifen, alone or in combination (ATAC) trial (18233230)EASTELL, Richard; HANNON, Rosemary A; CUZICK, Jack et al.Journal of bone and mineral research (Print). 2006, Vol 21, Num 8, pp 1215-1223, issn 0884-0431, 9 p.Article